# Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

> **NCT00054275** · PHASE2 · COMPLETED · sponsor: **Paula Silverman, MD** · enrollment: 39 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00054275
- **Lead sponsor:** Paula Silverman, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2010-04
- **Final completion:** 2012-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00054275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00054275, "Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00054275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*